Karyopharm Reports Q1 Results, Short Cash Runway, and Key Clinical Milestones
KPTI has more than doubled off its 52-week low of $3.65.
Summary
Karyopharm Therapeutics reported Q1 2026 financial results with increased revenue and a reduced net loss, but disclosed a very short cash runway into late Q3 2026, intensifying its going concern warning, despite positive clinical trial progress.
Key Events · Earnings and Guidance · KPTI
-
Short Cash Runway Confirmed
The company's existing liquidity is expected to fund operating plans only into late in the third quarter of 2026, reinforcing the previously issued going concern warning.
-
Q1 Financial Results Reported
Total revenue for Q1 2026 increased to $35.1 million from $30.0 million in Q1 2025. Net loss improved to $22.4 million, or $1.24 per diluted share, compared to $23.5 million, or $2.77 per diluted share, in the prior year period.
-
Myelofibrosis Trial Shows Promising Survival Signal
Phase 3 SENTRY trial results for myelofibrosis, while mixed on co-primary endpoints, showed a promising overall survival signal and will be presented at ASCO on June 2.
-
Endometrial Cancer Trial Enrollment Completed
Enrollment for the Phase 3 XPORT-EC-042 trial in endometrial cancer has been completed, with topline data expected in mid-2026.
Analysis · KPTI · Life Sciences
Karyopharm Therapeutics reported first-quarter results showing increased revenue and a reduced net loss, but the company's liquidity is projected to fund operations only into late Q3 2026. This extremely short cash runway reinforces the existing going concern warning, indicating significant financial pressure. While positive clinical trial updates, including completed enrollment for an endometrial cancer trial and a promising overall survival signal from a myelofibrosis trial, offer potential future value, they do not immediately resolve the critical near-term funding challenge.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KPTI was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.5M. The 52-week trading range was $3.65 to $10.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.